NCT02060474View on ClinicalTrials.gov

Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 26, 2018

Study Completion Date

June 26, 2018

Conditions
Allan-Herndon-Dudley Syndrome
Interventions
DRUG

Triac

Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.

Trial Locations (1)

3000 CA

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Erasmus Medical Center

OTHER